Evidence map›Paper›PMID 40343423›Full record

ArticleInfection & chemotherapy2025

Immune Responses Against SARS-CoV-2 in Previously SARS-CoV-2-Infected Individuals after Receiving a Single Dose of CoronaVac or ChAdOx-1 Vaccine.

Witida Laopajon, Athavudh Deesomchok, Warawut Chaiwong, Nuchjira Takheaw, Supansa Pata, Pilaiporn Duangjit, Juthamas Inchai, Chaicharn Pothirat, Chaiwat Bumroongkit, Theerakorn Theerakittikul and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection & chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Witida Laopajon *Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0002-5621-461X
Athavudh Deesomchok *Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0003-1375-4541
Warawut ChaiwongDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0003-4459-7681
Nuchjira TakheawDivision of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0002-7239-9482
Supansa PataDivision of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0001-8529-4332
Pilaiporn DuangjitDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Juthamas InchaiDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0001-5497-7704
Chaicharn PothiratDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0003-0616-7066
Chaiwat BumroongkitDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Theerakorn TheerakittikulDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Atikun LimsukonDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0001-7995-8649
Pattraporn TajarernmuangDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0003-4409-1832
Nutchanok NiyatiwatchanchaiDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Konlawij TrongtrakulDivision of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0002-2544-7322
Kantinan ChuensirikulchaiDepartment of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0009-0002-1141-6485
Passaworn CheyasawanDivision of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0009-0009-6357-4515
Chalerm Liwsrisakun *Division of Pulmonary, Critical Care, and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. chalerm.liw@cmu.ac.th.ORCID https://orcid.org/0000-0001-8376-2147
Watchara Kasinrerk *Division of Clinical Immunology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.ORCID https://orcid.org/0000-0003-0316-1531

Funding

Faculty of Medicine, Chiang Mai University 152/2564
6 · The paper itself

Abstract

backgroundAlthough infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) could induce natural immunity, previously infected individuals were suggested to have additional vaccination to enhance immune responses against the new variants of concern (VOCs). In this study, we determined the effects of a single dose of inactivated vaccine and viral vector-based vaccine on the neutralizing antibody (NAb) and T cell responses against the wild type (WT) and VOCs in the post-infection individuals. MATERIALS AND

methodsThe levels of NAb and specific T cell responses against the WT and VOCs of the previously infected individuals were determined before and after vaccination with a single dose of CoronaVac (CoVac) or ChAdOx-1 (ChAd) vaccine.

resultsEighteen subjects, with nine participants in each vaccination group, were recruited in this study. The CoVac group was significantly older (53.3±12.8

conclusionIn post-SARS-CoV-2 infection, ChAd vaccination induced a better antibody response, but the CoVac vaccine induced greater T-cell responses. Vaccination is valuable in boosting immunity, particularly against some VOCs, in individuals with prior SARS-CoV-2 infection.

trial registrationThis study was registered by the Clinical Trials Registry TCTR20210822002.

Indexed as

COVID-19Neutralizing antibodyPost SARS-CoV-2 infectionT cell responsesVaccination

Identifiers

PMID40343423
PMCPMC12230400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.